Profile

Michael C V Jensen, MD

Michael C V Jensen, MD

Children's Title: Director, Ben Towne Center for Childhood Cancer Research; Janet and Jim Sinegal Endowed Chair in Pediatric Solid Tumor Research in honor of Korey Rose

Academic Title: Professor

Research Center: Ben Towne Center for Childhood Cancer Research

Michael Jensen, MD, is director of the Ben Towne Center for Childhood Cancer at Seattle Childrens Research Institute and professor of hematology-oncology at the University of Washington School of Medicine. He is member of the clinical division in the Program in Immunology at Fred Hutchinson Cancer Research Center (FHCRC). Jensen holds the Janet and Jim Sinegal Endowed Chair in Pediatric Solid Tumor Research in Honor of Korey Rose.

Dr. Michael Jensen graduated from the University of Pennsylvania School of Medicine then completed training in Pediatric Hematology and Oncology at the University of Washington/Fred Hutchinson Cancer Research Center. His laboratory work began under the mentorship of Dr. Philip Greenberg, Program Head in Immunology, FHCRC and focused on the immunobiology of tumor-specific T-cells. Following completion of his fellowship, Dr. Jensen joined the faculty at the City of Hope National Medical Center where he built a translational research program integrating gene therapy and cellular immunotherapy for cancer. This program grew in to the Department of Cancer Immunotherapeutics & Tumor Immunology within the Beckman Research Institute and was incorporated into the institutions NCI-Comprehensive Cancer Center as the Cancer Immunotherapeutics Program with Dr Jensen as its leader. During his tenure at City of Hope, Dr Jensens research program placed a strong emphasis on bench-to-bedside translational research and resulted in seven FDA-authorized Investigational New Drug Applications covering first-in-human applications of adoptive transfer of genetically engineered T-cells having re-directed tumor specificity for lymphoma, neuroblastoma, and malignant gliomas. In 2010, Dr Jensen joined the University of Washington School of Medicine faculty as a Professor of Pediatrics and is the founding director of the Ben Towne Center for Childhood Cancer Research. He holds the Janet and Jim Sinegal endowed chair in pediatric cancer research. Dr. Jensen is an Adjunct Professor of Bioengineering and Neurological Surgery at the University of Washington School of Medicine and a Joint Member of the Clinical Research Division at Fred Hutchinson Cancer Research Center. Dr. Jensen is an Associate Head of the Immunology and Vaccine Development Program of the UW-FHCRC Cancer Consortium and is a SU2C Dream Team Principal Investigator on the recently awarded Pediatric Cancer Research Immunogenomics Dream Team award.

Making A Difference

  • Spearheading New Cancer Therapy

    Seattle Children’s takes a step toward revolutionizing the way cancer is treated with the hospital’s first reprogrammed T cell immunotherapy trial for relapsed leukemia.   ... cont.

  • Families Fuel Discovery

    Many rare and devastating diseases lack effective treatments or cures. The faith, funds and passion of families of our patients jump-start the search for answers that will help seriously ill children lead healthier lives. ... cont.

Overview

Medical/Professional School

University of Pennsylvania School of Medicine, Philadelphia

Residency

Pediatrics, Children's Hospital of Northern California, Oakland

Fellowship

Pediatric Hematology-Oncology, University of Washington, Seattle

Lab URL

http://www.seattlechildrens.org/research/childhood-cancer/our-science/our-labs/jensen-lab

Research Focus Area

Cancer

Publications

  • Jensen MC, Riddell SR
    Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.
    Immunological reviews , 2014 Jan. : 257(1)127-44
  • Budde LE, Berger C, Lin Y, Wang J, Lin X, Frayo SE, Brouns SA, Spencer DM, Till BG, Jensen MC, Riddell SR, Press OW
    Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma.
    PloS one , 2013 Dec. 17 : 8(12)e82742
  • Hunter MR, Prosser ME, Mahadev V, Wang X, Aguilar B, Brown CE, Forman SJ, Jensen MC
    Chimeric c cytokine receptors confer cytokine independent engraftment of human T lymphocytes.
    Molecular immunology , 2013 Nov. : 56(1-2)1-11
  • Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE, Hoffman L, Aguilar B, Chang WC, Bretzlaff W, Chang B, Jonnalagadda M, Starr R, Ostberg JR, Jensen MC, Bhatia R, Forman SJ
    T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.
    Blood , 2013 Oct. 31 : 122(18)3138-48
  • Hudecek M, Lupo-Stanghellini MT, Kosasih PL, Sommermeyer D, Jensen MC, Rader C, Riddell SR
    Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research , 2013 June 15 : 19(12)3153-64
  • Riddell SR, Jensen MC, June CH
    Chimeric antigen receptor--modified T cells: clinical translation in stem cell transplantation and beyond.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation , 2013 Jan. : 19(1 Suppl)S2-5
  • Jonnalagadda M, Brown CE, Chang WC, Ostberg JR, Forman SJ, Jensen MC
    Engineering human T cells for resistance to methotrexate and mycophenolate mofetil as an in vivo cell selection strategy.
    PloS one , 2013 : 8(6)e65519
  • Wang X, Naranjo A, Brown CE, Bautista C, Wong CW, Chang WC, Aguilar B, Ostberg JR, Riddell SR, Forman SJ, Jensen MC
    Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.
    Journal of immunotherapy (Hagerstown, Md. : 1997) , 2012 Nov. : 35(9)689-701
  • Turtle CJ, Hudecek M, Jensen MC, Riddell SR
    Engineered T cells for anti-cancer therapy.
    Current opinion in immunology , 2012 Oct. : 24(5)633-9
  • Prosser ME, Brown CE, Shami AF, Forman SJ, Jensen MC
    Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor.
    Molecular immunology , 2012 July : 51(3-4)263-72
  • Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, Lindgren CG, Lin Y, Pagel JM, Budde LE, Raubitschek A, Forman SJ, Greenberg PD, Riddell SR, Press OW
    CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.
    Blood , 2012 Apr, 26 : 119(17)3940-50
  • Brown CE, Starr R, Aguilar B, Shami AF, Martinez C, D'Apuzzo M, Barish ME, Forman SJ, Jensen MC
    Stem-like tumor-initiating cells isolated from IL13R2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research , 2012 Apr, 15 : 18(8)2199-209
  • Terakura S, Yamamoto TN, Gardner RA, Turtle CJ, Jensen MC, Riddell SR
    Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells.
    Blood , 2012 Jan. 5 : 119(1)72-82
  • Zou Z, Denny E, Brown CE, Jensen MC, Li G, Fujii T, Neman J, Jandial R, Chen M
    Cytotoxic T lymphocyte trafficking and survival in an augmented fibrin matrix carrier.
    PloS one , 2012 : 7(4)e34652
  • Wang X, Chang WC, Wong CW, Colcher D, Sherman M, Ostberg JR, Forman SJ, Riddell SR, Jensen MC
    A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells.
    Blood , 2011 Aug. 4 : 118(5)1255-63
  • Wang X, Berger C, Wong CW, Forman SJ, Riddell SR, Jensen MC
    Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice.
    Blood , 2011 Feb. 10 : 117(6)1888-98
  • Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, Bleakley M, Turtle CJ, Chang WC, Greisman HA, Wood B, Maloney DG, Jensen MC, Rader C, Riddell SR
    The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.
    Blood , 2010 Nov. 25 : 116(22)4532-41
  • Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, Ostberg JR, Forman SJ
    Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation , 2010 Sept. : 16(9)1245-56
  • Alizadeh D, Zhang L, Brown CE, Farrukh O, Jensen MC, Badie B
    Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research , 2010 July 1 : 16(13)3399-408
  • Cao LF, Krymskaya L, Tran V, Mi S, Jensen MC, Blanchard S, Kalos M
    Development and application of a multiplexable flow cytometry-based assay to quantify cell-mediated cytolysis.
    Cytometry. Part A : the journal of the International Society for Analytical Cytology , 2010 June : 77(6)534-45
  • Chen YY, Jensen MC, Smolke CD
    Genetic control of mammalian T-cell proliferation with synthetic RNA regulatory systems.
    Proceedings of the National Academy of Sciences of the United States of America , 2010 May 11 : 107(19)8531-6
  • James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Budde LE, Till BG, Raubitschek AA, Forman SJ, Press OW
    Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation.
    Journal of immunology (Baltimore, Md. : 1950) , 2010 Apr, 15 : 184(8)4284-94
  • James SE, Orgun NN, Tedder TF, Shlomchik MJ, Jensen MC, Lin Y, Greenberg PD, Press OW
    Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice.
    Blood , 2009 Dec. 24 : 114(27)5454-63
  • Brown CE, Starr R, Martinez C, Aguilar B, D'Apuzzo M, Todorov I, Shih CC, Badie B, Hudecek M, Riddell SR, Jensen MC
    Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells.
    Cancer research , 2009 Dec. 1 : 69(23)8886-93
  • Berger C, Berger M, Hackman RC, Gough M, Elliott C, Jensen MC, Riddell SR
    Safety and immunologic effects of IL-15 administration in nonhuman primates.
    Blood , 2009 Sept. 17 : 114(12)2417-26
  • Berger C, Turtle CJ, Jensen MC, Riddell SR
    Adoptive transfer of virus-specific and tumor-specific T cell immunity.
    Current opinion in immunology , 2009 Apr, : 21(2)224-32
  • Yaghoubi SS, Jensen MC, Satyamurthy N, Budhiraja S, Paik D, Czernin J, Gambhir SS
    Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma.
    Nature clinical practice. Oncology , 2009 Jan. : 6(1)53-8
  • Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, Qian X, James SE, Raubitschek A, Forman SJ, Gopal AK, Pagel JM, Lindgren CG, Greenberg PD, Riddell SR, Press OW
    Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.
    Blood , 2008 Sept. 15 : 112(6)2261-71
  • Lazovic J, Jensen MC, Ferkassian E, Aguilar B, Raubitschek A, Jacobs RE
    Imaging immune response in vivo: cytolytic action of genetically altered T cells directed to glioblastoma multiforme.
    Clinical cancer research : an official journal of the American Association for Cancer Research , 2008 June 15 : 14(12)3832-9
  • James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Till BG, Raubitschek AA, Forman SJ, Press OW
    Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane.
    Journal of immunology (Baltimore, Md. : 1950) , 2008 May 15 : 180(10)7028-38
  • Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR
    Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates.
    The Journal of clinical investigation , 2008 Jan. : 118(1)294-305
  • Jensen MC
    Engineering GVL through T cell gene transfer.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation , 2008 Jan. : 14(1 Suppl 1)5
  • Stastny MJ, Brown CE, Ruel C, Jensen MC
    Medulloblastomas expressing IL13Ralpha2 are targets for IL13-zetakine+ cytolytic T cells.
    Journal of pediatric hematology/oncology , 2007 Oct. : 29(10)669-77
  • Tran CA, Burton L, Russom D, Wagner JR, Jensen MC, Forman SJ, DiGiusto DL
    Manufacturing of large numbers of patient-specific T cells for adoptive immunotherapy: an approach to improving product safety, composition, and production capacity.
    Journal of immunotherapy (Hagerstown, Md. : 1997) , 2007 Sept. : 30(6)644-54
  • Brown CE, Vishwanath RP, Aguilar B, Starr R, Najbauer J, Aboody KS, Jensen MC
    Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells.
    Journal of immunology (Baltimore, Md. : 1950) , 2007 Sept. 1 : 179(5)3332-41
  • Numbenjapon T, Serrano LM, Chang WC, Forman SJ, Jensen MC, Cooper LJ
    Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cells.
    Experimental hematology , 2007 July : 35(7)1083-90
  • Park JR, Digiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, Meechoovet HB, Bautista C, Chang WC, Ostberg JR, Jensen MC
    Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma.
    Molecular therapy : the journal of the American Society of Gene Therapy , 2007 Apr, : 15(4)825-33
  • Singh H, Serrano LM, Pfeiffer T, Olivares S, McNamara G, Smith DD, Al-Kadhimi Z, Forman SJ, Gillies SD, Jensen MC, Colcher D, Raubitschek A, Cooper LJ
    Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy.
    Cancer research , 2007 Mar. 15 : 67(6)2872-80
  • Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, Mischel PS, Stokoe D, Pieper RO
    Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma.
    Nature medicine , 2007 Jan. : 13(1)84-8
  • Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, Smith DD, Forman SJ, Jensen MC, Cooper LJ
    CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
    Cancer research , 2006 Nov. 15 : 66(22)10995-1004
  • Otto-Duessel M, Khankaldyyan V, Gonzalez-Gomez I, Jensen MC, Laug WE, Rosol M
    In vivo testing of Renilla luciferase substrate analogs in an orthotopic murine model of human glioblastoma.
    Molecular imaging , 2006 Apr, : 5(2)57-64
  • Serrano LM, Pfeiffer T, Olivares S, Numbenjapon T, Bennitt J, Kim D, Smith D, McNamara G, Al-Kadhimi Z, Rosenthal J, Forman SJ, Jensen MC, Cooper LJ
    Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy.
    Blood , 2006 Apr, 1 : 107(7)2643-52
  • Vishwanath RP, Brown CE, Wagner JR, Meechoovet HB, Naranjo A, Wright CL, Olivares S, Qian D, Cooper LJ, Jensen MC
    A quantitative high-throughput chemotaxis assay using bioluminescent reporter cells.
    Journal of immunological methods , 2005 July : 302(1-2)78-89
  • Gonzalez S, Castanotto D, Li H, Olivares S, Jensen MC, Forman SJ, Rossi JJ, Cooper LJ
    Amplification of RNAi--targeting HLA mRNAs.
    Molecular therapy : the journal of the American Society of Gene Therapy , 2005 May : 11(5)811-8
  • Cooper LJ, Al-Kadhimi Z, Serrano LM, Pfeiffer T, Olivares S, Castro A, Chang WC, Gonzalez S, Smith D, Forman SJ, Jensen MC
    Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1.
    Blood , 2005 Feb. 15 : 105(4)1622-31
  • Brown CE, Wright CL, Naranjo A, Vishwanath RP, Chang WC, Olivares S, Wagner JR, Bruins L, Raubitschek A, Cooper LJ, Jensen MC
    Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing.
    Journal of immunological methods , 2005 Feb. : 297(1-2)39-52
  • Cooper LJ, Kalos M, DiGiusto D, Brown C, Forman SJ, Raubitschek A, Jensen MC
    T-cell genetic modification for re-directed tumor recognition.
    Cancer chemotherapy and biological response modifiers , 2005 : 22293-324
  • Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC
    Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
    Cancer research , 2004 Dec. 15 : 64(24)9160-6
  • Cooper LJ, Topp MS, Pinzon C, Plavec I, Jensen MC, Riddell SR, Greenberg PD
    Enhanced transgene expression in quiescent and activated human CD8+ T cells.
    Human gene therapy , 2004 July : 15(7)648-58
  • Cooper LJ, Al-Kadhimi Z, DiGiusto D, Kalos M, Colcher D, Raubitschek A, Forman SJ, Jensen MC
    Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies.
    Blood cells, molecules & diseases , 2004 July : 33(1)83-9
  • Gonzalez S, Naranjo A, Serrano LM, Chang WC, Wright CL, Jensen MC
    Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma.
    The journal of gene medicine , 2004 June : 6(6)704-11
  • Wang J, Press OW, Lindgren CG, Greenberg P, Riddell S, Qian X, Laugen C, Raubitschek A, Forman SJ, Jensen MC
    Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes.
    Molecular therapy : the journal of the American Society of Gene Therapy , 2004 Apr, : 9(4)577-86
  • Topp MS, Riddell SR, Akatsuka Y, Jensen MC, Blattman JN, Greenberg PD
    Restoration of CD28 expression in CD28- CD8+ memory effector T cells reconstitutes antigen-induced IL-2 production.
    The Journal of experimental medicine , 2003 Sept. 15 : 198(6)947-55
  • Cooper LJ, Topp MS, Serrano LM, Gonzalez S, Chang WC, Naranjo A, Wright C, Popplewell L, Raubitschek A, Forman SJ, Jensen MC
    T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect.
    Blood , 2003 Feb. 15 : 101(4)1637-44